Member Info for Toukankahmoon

13th

A rational analysis of what is going on rather than the solely wishful thinking of some.

As I have said many times if the the likes of Timster (who is actually quite knowledgeable though prefers to be the BB resident clown) would stop making ludicrous predictions then I wouldn’t feel the need to challenge them.

Also I presume that you aren’t abusive on Telegram or you’d be kicked off the group, so why don’t you stop being juvenile on here?

Wyndrum

13thmonkey is playing with you. You cannot search Telegram to find the group because it isn’t a public group. You have to be invited and although there are some knowledgeable and experienced members some still have a Pom Pom waving mentality and dislike anyone who questions the published ‘facts’. So I don’t think that we will ever be invited. This of course is ludicrous if they are putting themselves forward as a group that represents all or even most Avacta shareholders because it clearly doesn’t. What a surprise.

13th

Thank you for proving my point

Wyndrum

DTW is playing with you. You cannot search Telegram to find the group because it isn’t a public group. You have to be invited and although there are some knowledgeable and experienced members some still have a Pom Pom waving mentality and dislike anyone who questions the published ‘facts’. So I don’t think that we will ever be invited. This of course is ludicrous if they are putting themselves forward as a group that represents all or even most Avacta shareholders because it clearly doesn’t. What a surprise.

Lovable

You may well have hit the nail on the head. Here’s hoping👍

Ice

Reread the first post in this thread and you will see what I am objecting to. I thought we had all agreed that the platform works but more trials are required to prove AVA6000 efficacy.

How is “doxirubicin (sic) is already approved “ news in any shape or form?😄

Great informative post shame about misleading title.

Ice

It’s easy, it’s because the incessant baseless ramping gets repeated endlessly everyday. 😄

Jeez I’m glad we are not discussing doxorubicin 🤣🤣🤣

What a well researched poster.

Cj62

Yep it’s a deal. No more delusional fantastic baseless ramping and I will keep quiet.

Anyhow hopefully next week’s webinar will be unambiguous so won’t be anything to argue about.

Cj62

But that is just the point. To be of use the BB needs to discuss the pros and cons not just be a Pom Pom waving fan club making ridiculous statements about what might happen. Neither should it be viciously abusive.

None of the so-called fudsters make personal attacks in their posts.

Why the realists on here inspire such vitriol escapes me.

I will restate my views for clarity:

1. The platform works

2. Proof of efficacy of AVA6000 needs more trial data

3. Al has said he is taking AVA6000 all the way

4. Deals will be done for AVA3996

5. P2 data will be needed before significant SP movement

So what of the above constitutes “Univested vermin who take pleasure in others misfortune and run avacta to the ground”?

Or are you just going to resort to childish jibes as usual?

#Gracie this one’s for you!

Thompi

Thanks. Didn’t check the Vox interview

Tim

The answer as always is that we don’t know. That is the point of the clinical trials and helps explain why the SP is what it is.

I am not sure Avacta ever stated “ . . . P1a exceeded all expectations“.

Even if they did, what does it mean? The mouse trial results were excellent. I haven’t seen any data that says human trial results weren’t as good. Tumour targeting was expected to be very precise so I don’t see why they were surprised that high dosing would be required in humans before reaching the OMD. Originally we told c5 would be the end. This better all become clear in the AACR presentation.

Derbyone

Give me an example of my daily tripe? Do you mean:

1. Although the platform is proven, AVA6000 efficacy has not been proven in significant numbers.

2. There is still a long way to go before we get a decent dividend

Or is it Pom Pom girl tripe like:

1. Take over next week

2. £10 by Wednesday

3. Hugely impressive data to be published at AACR

Don’t bother to reply. It’s clear which camp you are in.

The saving grace will be if we get more data on more patients including C7 results. But I think all hopes are pinned on arm2 which counteracts speed of dox excretion by dosing every 2 weeks. If that doesn’t show efficacy then there is always weekly dosing which, at the excellent safety AVA6000 has shown, I presume is a possibility.

Yep. Except I think the rich data showing consistently high efficacy across a significant number of patients is what will decide that Avacta is successful.

Get signed up. All our questions will be answered

Wow

Super exciting. The webinar and questions. Will they all be answered